Fujian Haixi Pharmaceutical Co., Ltd. (“Haixi Pharmaceutical”, 02637.HK) was founded in 2012 and has grown to a commercial-stage innovative pharmaceutical company covering the entire industrial chain of R&D, clinical research, manufacturing and commercialization. The company was successfully listed on the Main Board of The Stock Exchange of Hong Kong on October 20, 2025, and was included in the Hong Kong Stock Connect on March 9, 2026.

       Our company adheres to the development philosophy of “Generics empower innovation, innovation drives the future”, and fosters synergy between generics and innovative drugs.

       In the field of generic drugs, the company focuses on the development of first-to-file, difficult-to-make generics and high-value generics. As of March 2026, 15 products have been approved to be on market. Four core products, namely Mosapride Citrate Tablets (Anbili®), Cinacalcet Hydrochloride Tablets (Ruiantuo®), Amlodipine Besylate and Atorvastatin Calcium Tablets (Haihuitong®) and Hydroxychloroquine Sulfate Tablets (Saixifu®), have successfully won bids in the 4th, 5th, 8th and 10th rounds of National VBP (Volume Based Pruchase) Schemes respectively, forming a stable revenue stream to sustain the R&D of innovative drugs.

       For innovative drugs, the company has independently developed the MultiSel-Opt small-molecule innovative drug R&D platform, which enables a single drug molecule to selectively act on multiple protein targets for synergistic therapeutic mechanisms. HXP056, a small-molecule drug developed on this platform, is currently in Phase I/II clinical development. It is intended for the treatment of retinal diseases related to neovascularization, including wet age-related macular degeneration (nAMD), diabetic macular edema (DME) and retinal vein occlusion (RVO), and is expected to become the world’s first oral innovative drug for these indications. C019199, an oncology candidate, will commence Phase III clinical trials for osteosarcoma in China in H1 2026, aiming to provide an urgently needed therapeutic option for osteosarcoma patients.

       Led by Dr. Xinshan Kang , the company has assembled a high-level talent team and strengthened industry-university-research cooperation. It has been recognized as a National High-Tech Enterprise, a National Specialized, Refined, Differential and Innovative “Little Giant” Enterprise, and the first enterprise in Fujian Province to obtain a Category B Drug Production License after the major reform in China, and holds more than 30 invention patents.

       Looking ahead, Haixi Pharma will continue to uphold the corporate spirit of “Hard-Working with Result-Oriented”, adhere to its core values of“Innovation, Integrity, Sharing and Benevolence”. Grounded in reality at the same time aiming high, we will keep developing a rich portfolio of globally competitive innovative medicines, striving to realize our vision: “Best Medicine Made Available to People”.